This indicates that, in contrast to a prior observational study that reported a higher risk of HPD with ICI monotherapy for pre‐treated HCC,9 frontline ICI use in combination with VEGF‐targeted therapy appears unlikely to cause excess HPD in HCC. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.